Serum glial fibrillary acidic protein indicates memory impairment in patients with chronic heart failure.

ABSTRACT:

Aims

Cognitive dysfunction occurs frequently in patients with heart failure (HF), but early detection remains challenging. Serum glial fibrillary acidic protein (GFAP) is an emerging biomarker of cognitive decline in disorders of primary neurodegeneration such as Alzheimer's disease. We evaluated the utility of serum GFAP as a biomarker for cognitive dysfunction and structural brain damage in patients with stable chronic HF.

Methods and results

Using bead-based single molecule immunoassays, we quantified serum levels of GFAP in patients with HF participating in the prospective Cognition.Matters-HF study. Participants were extensively phenotyped, including cognitive testing of five separate domains and magnetic resonance imaging (MRI) of the brain. Univariable and multivariab

SUBMITTER: Traub J 

PROVIDER: S-EPMC9288738 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature